Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P240004/S001

EndoForce Connector for Endovascular Venous Anastomosis

Phraxis, Inc. · Decision date Jul 18, 2025

FDA DECISIONP240004/S001

What did the FDA approve?

FDA records P240004/S001 as a supplement to PMA P240004, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Jul 18, 2025.

FDA approval order statement

Approval of the protocol for the EndoForce Post-Approval Study submitted to comply with the conditions of approval outlined in the approval order for P240004.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Cardiovascular
Decision date
Jul 18, 2025
FDA change category
Postapproval Study Protocol

FDA source record

Regulatory record facts

Identifier
P240004/S001
Regulatory pathway
PMA supplement
Applicant
Phraxis, Inc.
Product code
SEQ
Decision code
APPR
Decision date
Jul 18, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Covered stent vascular connector, hemodialysis access circuit.

Applicant
Phraxis, Inc.
Product code
SEQ
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P240004/S001 received

    Application receipt date recorded by FDA.

  2. P240004/S001 · FDA decision

    Normal 180 Day Track No User Fee

Timeline entries are records held by MedtechLedger for P240004. View FDA’s full supplement list.

Related devices and submissions

Explore the linked device profile

No additional submissions with a verified PMA or product-code relationship are linked here.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Phraxis, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
333 Hennepin Ave. E., Minneapolis, MN, 55114

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records